Skip to main content

In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y.

Publication ,  Journal Article
Kelsey, MD; Newby, LK
Published in: Ann Intern Med
November 2022

Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 202;400:380-90. 35863366.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

November 2022

Volume

175

Issue

11

Start / End Page

JC126

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Randomized Controlled Trials as Topic
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General & Internal Medicine
  • Ezetimibe
  • Equivalence Trials as Topic
  • Drug Therapy, Combination
  • Atherosclerosis
  • Anticholesteremic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kelsey, M. D., & Newby, L. K. (2022). In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y. Ann Intern Med, 175(11), JC126. https://doi.org/10.7326/J22-0085
Kelsey, Michelle D., and L Kristin Newby. “In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y.Ann Intern Med 175, no. 11 (November 2022): JC126. https://doi.org/10.7326/J22-0085.
Kelsey, Michelle D., and L. Kristin Newby. “In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y.Ann Intern Med, vol. 175, no. 11, Nov. 2022, p. JC126. Pubmed, doi:10.7326/J22-0085.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

November 2022

Volume

175

Issue

11

Start / End Page

JC126

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Randomized Controlled Trials as Topic
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General & Internal Medicine
  • Ezetimibe
  • Equivalence Trials as Topic
  • Drug Therapy, Combination
  • Atherosclerosis
  • Anticholesteremic Agents